Drugs / NBM-BMX
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03808870 | Dec 2018 → Feb 2022 | cancer | NatureWise Biotech & Medicals Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03726294 | Oct 2018 → Apr 2020 | cancer | NatureWise Biotech & Medicals Corporation | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07569042 | Apr 2026 → Sep 2029 expected | brain cancer | Novelwise Pharmaceutical Corporation | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07136181 | Nov 2025 → Mar 2028 expected | uveal melanoma | Novelwise Pharmaceutical Corporation | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06012695 | Aug 2023 → May 2028 expected | brain cancer | Novelwise Pharmaceutical Corporation | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NBM-BMX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07136181 ↗ |
| Action | Inhibit | “NBM-BMX is a histone deacetylase (HDAC) inhibitor” NCT03726294 ↗ |
| Modality | Small molecule | “NBM-BMX is a new small molecule chemical entity” NCT03726294 ↗ |
| Route | Oral | “Patients will initially receive NBM-BMX orally once a day at 100 mg per day.” NCT03726294 ↗ |
| Target | HDAC8 | “particularly active against HDAC8” NCT03726294 ↗ |